MedRhythms Unveils Movive™ for Parkinson's Disease Rehabilitation
MedRhythms has officially announced the listing of MR-005, also known as Movive™, as a Class II medical device by the U.S. Food and Drug Administration (FDA). This innovative neurorehabilitation tool, specifically designed to enhance gait rehabilitation for adults suffering from Parkinson's disease (PD), marks a significant milestone in the company's commitment to integrating music with therapeutic solutions.
The Impact of Movive™ on Patient Mobility
Movive™ harnesses the power of rhythmic auditory stimulation (RAS), a well-researched method known to assist individuals with PD. According to Brian Harris, Co-Founder and CEO of MedRhythms, this development is a pivotal moment in their mission to improve mobility for individuals experiencing neurologic challenges. The combination of music and technology aims to directly address mobility issues encountered by many patients, providing an exciting potential for rehabilitation.
Understanding Parkinson's Disease Challenges
Parkinson's disease is recognized as the fastest-growing neurodegenerative disorder globally, with nearly one million Americans affected, including a notable population of Veterans. Symptoms such as gait impairment and loss of motor function frequently hinder daily activities. Movive™ is expected to play a crucial role in meeting the urgent need for effective therapeutic tools that personalize the rehabilitation process.
Features of Movive™
Movive™ is designed to make RAS more widely accessible, allowing for tailored and engaging therapy that patients can use independently at home. Its development focuses on ensuring that individuals can incorporate this therapy into their daily lives, promoting continued engagement and progress.
Looking Ahead to Market Launch
MedRhythms is preparing for the launch of Movive™ in select markets within the United States in the second quarter of 2025. As anticipation builds, the company encourages those interested in learning more about Movive™ and its functionality to visit their official site.
Join the Conversation
MedRhythms will be present at the upcoming Association of VA Neurology Services Annual Meeting, offering a valuable opportunity to engage with healthcare professionals and share insights about this groundbreaking technology.
About MedRhythms
MedRhythms is at the forefront of developing cutting-edge neurotherapeutics aimed at enhancing mobility through a proprietary technology platform that combines innovative sensors, software, and music. With advanced neuroscience guiding their approach, they are working towards making significant advancements in treating a variety of neurological conditions, including stroke and multiple sclerosis, in addition to Parkinson's disease.
In 2020, the company received Breakthrough Device Designation for their product addressing chronic stroke walking deficits, further emphasizing their commitment to improving patient outcomes. Their approach involves a partnership with Universal Music Group, showcasing the fusion of creativity and science in their therapeutic offerings.
Frequently Asked Questions
What is Movive™?
Movive™ is a neurorehabilitation system developed by MedRhythms to assist gait rehabilitation for individuals with Parkinson's disease.
When is Movive™ expected to launch?
The anticipated launch for Movive™ is in select U.S. markets in Q2 2025.
How does Movive™ support patients?
Movive™ utilizes rhythmic auditory stimulation to enhance gait and motor function, making therapeutic sessions more engaging and personalized.
Who can benefit from Movive™?
Individuals with Parkinson's disease facing challenges with mobility and motor functions can significantly benefit from Movive™.
What is the mission of MedRhythms?
MedRhythms aims to leverage music to improve mobility and rehabilitation for those with neurologic injuries and diseases.
